Refine Results
Sort By
From
To
Page 2
Page 2
Cancer Proteomics : From Bench to Bedside
the authors collectively provide the current status of proteomics in cancer therapy and offers the existing technologies used in proteomics that allow for protein profiling and for the identification of druggable targets in human samples. Mass spectrometry based protein characterization and protein microarrays hold great promise of predicting response to specific drugs in cancer therapy. Insightful to the reader with broad perspectives on topics related to the use of proteomic strategies in cancer therapy, Cancer Proteomics offers anticipated challenges that may arise from its application in daily practice.
Cancer drug safety and public health policy : A changing landscape
Description and analysis of recent developments and current trends in health policy with regard to cancer drug safety. Opens with an overview of pharmacovigilance for cancer blockbuster drugs, covering both general considerations and efforts to develop a structured framework for the identification and reporting of adverse drug reactions (ADRs). A number of important examples of serious ADRs to hematology and oncology drugs are then reviewed, with evaluation of the lessons learned and the policy implications of the ensuing legal cases and their settlements. Further, the difficulty of reporting such blockbuster side effects in the medical literature is explored in an empirical study. Significant advances have been achieved in analytic methods for the identification of ADRs, and here there is a particular focus on the value of optimal discriminant analysis. Finally, the impacts on pharmacovigilance and drug safety of the huge fines paid under the U.S. False Claims Act relating to the defrauding of governmental programs also receive careful attention – these fines are playing an important role in changing the landscape for pharmaceutical safety.
CADD and informatics in drug discovery
Updates knowledge on recent advances in computational and bioinformatics tools/techniques and their practical applications in modern drug design and discovery programme. Also it encompasses fundamental principles, advanced methodologies and applications of various CADD approaches including several cutting-edge areas / presenting recent developments covering ongoing trends in the field of computer-aided drug discovery. Having contributions by a global team of experts, the book is expected to be an ideal resource for drug discovery scientists, medicinal chemists, pharmacologists, toxicologists, phytochemists, biochemists, biologists, RandD personnel, researchers, students, teachers and those working in the field of drug discovery. It will fill the knowledge gaps that exist in the current CADD approaches and methodologies/ protocols being widely used in both academic and research practices. Further, a special focus on current status of various computational drug design approaches (SBDD, LBDD, De-novo drug design, Pharmacophore-based search), bioinformatics tools and databases, computational screening and modeling of phytochemicals/natural products, artificial intelligence and machine learning, and network pharmacology and system biology would certainly guide researchers, students or readers to conduct their research in the emerging area(s) of interest. It is also expected to be highly beneficial to different stakeholders working in the pharmaceutical and biotechnology industries (RandD), the academic as well as research sectors. .
Brain and Heart Dynamics
Despite the increasing awareness that neural mechanisms are the primary cause of cardiac disease and its progression, therapy continues to focus on end-organ protection and does not approach the neural core of the problem. Growing public health problems such as heart failure are still treated with autonomic drugs that are 30-40 years old and simply act on cardiac receptors. However, it has now been shown that the progression of ischemic heart disease to heart failure is mainly due to abnormal central responses to incipient cardiac disease, with neural activation the primary cause rather than the consequence of cardiac remodeling.
Botanical drug products : Recent developments and market trends
Botanicals, which have been part of human food and medicine for thousands of years, are perceived as being safer than synthetic pharmaceuticals. The global botanical drug market was expected to reach $26.6 billion by 2017. In terms of FDA regulations, botanical drugs are no different from non-botanical products, having to meet the safety and effectiveness standards of a new drug in accordance. This book comprises a complete start-to-end process from drug-idea conception, to drug development process.
Biopharmaceutics applications in drug development
This book introduces fundamental concepts, methods, and advances in the areas of dissolution, absorption, and permeability and their key applications in dosage form performance. Case studies are used to discuss the applications of biopharmaceutic strategies in the development of successful drugs, with a specific focus on the applications of biopharmaceutic strategies in the development of successful drugs. The book presents an integrated view in linking pharmaceutic to the biological consequences of drug products and leverages those for decision making in drug development.
Biopharmaceutics : From fundamentals to industrial practice
Beginning with an expansive introduction to the basics of biopharmaceutics and the context that underpins the field, the included resources go on to discuss how biopharmaceutics are integrated into product development within the pharmaceutical industry. Explorations of how the regulatory aspects of biopharmaceutics function, as well as the impact of physiology and anatomy on the rate and extent of drug absorption, follow.
Biopharmaceutical processing : Development, design, and Implementation of manufacturing processes
Biopharmaceutical Processing: Development, Design, and Implementation of Manufacturing Processes covers bioprocessing from cell line development to bulk drug substances. The methods and strategies described are essential learning for every scientist, engineer or manager in the biopharmaceutical and vaccines industry. The integrity of the bioprocess ultimately determines the quality of the product in the biotherapeutics arena, and this book covers every stage including all technologies related to downstream purification and upstream processing fields. Economic considerations are included throughout, with recommendations for lowering costs and improving efficiencies.
Biopharmaceutical drug design and development
Biopharmaceutical Drug Design and Development, Second Edition, updates the widely successful first edition, published in 1999. This new, expanded edition investigates the dozens of new biopharmaceutical drugs that have become available since the publication of the first edition. Among the drugs discussed are ones in the categories of monoclonal antibodies for in-vivo use, cytokines, growth factors, enzymes, immunomodulators, thrombolytics, and immonotherapies including vaccines. Additionally, the volume examines new and emerging technologies, such as bioinformatics, DNA microarrays, transgenics, therapeutic gene delivery, stem cells, nucleic acid-based therapeutics, and macromolecular drug delivery. Authors also study pharmacogenetics in the clinic and changes in biologic drug approval at the FDA. Biopharmaceutical Drug Design and Development, Second Edition, is a worthy sequel in the discussion on the dynamic, exciting field of biotechnology.
Biomedical applications and toxicity of nanomaterials
Covers the recent trends on the biological applications of nanomaterials, methods for their preparation, and techniques for their characterization. Further, the book examines the fundamentals of nanotoxicity, methods to assess the toxicity of engineered nanomaterials, approaches to reduce toxicity during synthesis. It also provides an overview of the state of the art in the application of Artificial intelligence-based methodologies for evaluation of toxicity of drugs and nanoparticles. The book further discusses nanocarrier design, routes of various nanoparticle administration, nano based drug delivery systems, and the toxicity challenges associated with each drug delivery method. It presents the latest advances in the interaction of nanoparticles with the cellular environment and assess nanotoxicity of these engineered nanoparticles. The book also explores the comparative and mechanistic genotoxicity assessment of the nanomaterials. This book is useful source of information for industrial practitioners, policy makers, and other professionals in the fields of toxicology, medicine, pharmacology, food, and drugs.
Biomarkers for alzheimer’s disease drug development
Aims to build a new generation of experts with a broader understanding of key topics in the Alzheimer’s disease field. Chapters guide readers through innovative approaches to the discovery of novel biomarkers in cerebrospinal fluid, innovation in blood-based biomarkers, a comprehensive overview of magnetic resonance imaging and molecular imaging approaches and their value for developing drugs for Alzheimer’s disease, cutting-edge developments in neuropathology and their relevance for Alzheimer’s disease trials, novel genomic strategies for biomarker development, and related topics including neuropsychological testing and advanced analytical methods.Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls.
Biomarkers as targeted herbal drug discovery : A pharmacological approach to nanomedicines
Looks at the applications of biomarkers as important tools for herbal drug discovery, presenting research on phytoconstituents with advanced nanotechnological applications for healthcare benefits. Herbal drug discovery based on biomarkers is an emerging area in complementary and alternative medicine that has tremendous potential in healthcare. Conventional medications have limited efficacy and high toxicity, whereas herbal drugs are said to provide wide structural diversity that is not usually seen with conventional/synthetic drug molecules. Recognition of various herbal constituents, such as terpenoids, fatty acids, flavonoids and steroids, are well explored in the management and treatment of various disorders in this volume. These agents target various biomarkers such as nitric oxide (NO), cytokines, chemokines, adhesion molecules, NF- kβ, lipoxygenase (LOX), and arachidonic acid. Reviews the literature on inflammatory biomarkers in the treatment of diseases Looks at the development of herbal drug discovery based on biomarkers Explores emerging concepts of nanomedicines for herbal drug delivery Takes an interdisciplinary approach, with application to disciplines related to medical, pharmaceutical, biotechnological, Ayurvedic, Unani and biomedical engineering fields
Biologics, biosimilars, and biobetters : An introduction for pharmacists, physicians and other health practitioners
Explains what pharmacists need to discuss the equivalence, efficacy, safety, and risks of biosimilars with physicians, health practitioners, and patients about Guides regulators on pragmatic approaches to dealing with these drugs in the context of rapidly evolving scientific and clinical evidence Balances scientific information on complex drugs with practical information, such as a checklist for pharmacists
Bioactives and pharmacology of lamiaceae
Provides a wealth of information on plants in the Lamiaceae family, noted for their essential oils and bioactives and pharmacological properties. The chapters investigate a wide variety of species, providing for each an introduction, characteristics, properties, distribution, traditional uses, and current and potential pharmacological applications. Aiming to be a resource for the development of new drugs based on species within the Lamiaceae family, the volume discusses 26 species, including bungleweed (Ajuga), Malabar catmint (Anisomeles malabarica), beechwood (Gmelina arborea), Brazilian mint (Hyptis crenata), rosemary (Rosmarinus officinalis L.), holy basil (Ocimum tenuiflorum), and many more.
Behavioral pharmacology of the cholinergic system
The molecular genetics of the cholinergic system including both muscarinic and nicotinic acetylcholine receptors, cholinesterases, acetylcholine synthesis and release have provided significant insights into potential targeting for pharmacological intervention. Cholinergic drugs are being used or evaluated for the treatment of diseases. Thus, this volume aims to broaden our understanding of the current state of cholinergic mechanisms to enable implementation of novel approaches for the development of more effective treatments.
Basiswissen pharmakologie = Basic knowledge of pharmacology
Offers a clear and concise overview of all exam-relevant pharmacology content. It guides you through the entire foundational knowledge, from the basics to the most important clinical pictures, in an easily understandable way and aligned with the German National Competency-Based Learning Objectives for Medicine (GK) and National Competency-Based Learning Objectives for Medicine (NKLM). Benefit from the lecturer's many years of experience, who has carefully selected and presented the essential information for you.
Basic pharmacokinetics
Introduces basic pharmacokinetic concepts to beginner learners to help them understand the absorption, distribution, metabolism, and excretion of drugs. Accompanying the book is a website with self-instructional tutorials and pharmacokinetic and pharmacokinetic-pharmacodynamic simulations, allowing visualization of concepts for enhanced comprehension. This learning tool received an award from the American Association of Colleges of Pharmacy for innovation in teaching, making it a valuable supplement to this essential text.
Basic knowledge of pharmacology
Concise and up-to-date coverage of the most important drugs Integration of experimental and clinical pharmacology with focus on diseases Discusses the most important drugs (400) in the context of relevant diseases. Summary tables and schemes, MCQ exam questions, case studies and a list of drugs aid memorization of the material before an exam. All chapters are written in the same concise style and use a modern and precise pharmacological nomenclature. After reading of the book, the student will be able to critically assess the proper use of the most important drugs and advise patients properly. The didactic concept of the book has been developed on the author’s own pharmacology courses for which he has received numerous teaching awards. The book takes advantage of the learning spiral, in which material is presented repeatedly from various angles.
Basic & Clinical Pharmacology
Covers the important concepts students need to know about the science of pharmacology and its application to clinical practice. This edition has been extensively updated to provide expanded coverage of transporters, pharmacogenomics, and new drugs Delivers the knowledge and insight needed to excel in every facet of pharmacology!. Encompasses all aspects of medical pharmacology, including botanicals and over-the-counter drugs Major revisions of the chapters on immunopharmacology, antiseizure, antipsychotic, antidepressant, antidiabetic, anti-inflammatory, and antiviral drugs, prostaglandins, and central nervous system neurotransmitters New chapter on the increasingly relevant topic of cannabis pharmacology Each chapter opens with a case study, covers drug groups and prototypes, and closes with summary tables and diagrams that encapsulate important information Revised full-color illustrations provide more information about drug mechanisms and effects and help clarify important concepts Trade Name/Generic Name tables are provided at end of each chapter for easy reference when writing a chart order or prescription Includes descriptions of important new drugs released through May 2019 New and updated coverage of general concepts relating to recently discovered receptors, receptor mechanisms, and drug transporters
Barile's clinical toxicology : Principles and mechanisms ; 3rd ed.
Examines the complex interactions associated with clinical toxicological events as a result of therapeutic drug administration or chemical exposure. Special emphasis is placed on signs and symptoms of diseases and pathology caused by toxins and clinical drugs. Includes the source, pharmacological and toxicological mechanism of action, detection and identification in body fluids, and treatment of exposure. An overview of protocols for managing various toxic ingestions, and the antidotes and treatments associated with their pathology, are discussed. In addition, effect of toxins on a limited number of body systems and drug-induced adverse drug reactions are also covered
